Literature DB >> 32498804

Limitations of Contemporary Guidelines for Managing Patients at High Genetic Risk of Coronary Artery Disease.

Krishna G Aragam1, Amanda Dobbyn2, Renae Judy3, Mark Chaffin4, Kumardeep Chaudhary2, George Hindy4, Andrew Cagan5, Phoebe Finneran6, Lu-Chen Weng7, Ruth J F Loos8, Girish Nadkarni2, Judy H Cho9, Rachel L Kember10, Aris Baras11, Jeffrey Reid11, John Overton11, Anthony Philippakis4, Patrick T Ellinor7, Scott T Weiss12, Daniel J Rader10, Steven A Lubitz7, Jordan W Smoller13, Elizabeth W Karlson14, Amit V Khera15, Sekar Kathiresan15, Ron Do16, Scott M Damrauer17, Pradeep Natarajan18.   

Abstract

BACKGROUND: Polygenic risk scores (PRS) for coronary artery disease (CAD) identify high-risk individuals more likely to benefit from primary prevention statin therapy. Whether polygenic CAD risk is captured by conventional paradigms for assessing clinical cardiovascular risk remains unclear.
OBJECTIVES: This study sought to intersect polygenic risk with guideline-based recommendations and management patterns for CAD primary prevention.
METHODS: A genome-wide CAD PRS was applied to 47,108 individuals across 3 U.S. health care systems. The authors then assessed whether primary prevention patients at high polygenic risk might be distinguished on the basis of greater guideline-recommended statin eligibility and higher rates of statin therapy.
RESULTS: Of 47,108 study participants, the mean age was 60 years, and 11,020 (23.4%) had CAD. The CAD PRS strongly associated with prevalent CAD (odds ratio: 1.4 per SD increase in PRS; p < 0.0001). High polygenic risk (top 20% of PRS) conferred 1.9-fold odds of developing CAD (p < 0.0001). However, among primary prevention patients (n = 33,251), high polygenic risk did not correspond with increased recommendations for statin therapy per the American College of Cardiology/American Heart Association (46.2% for those with high PRS vs. 46.8% for all others, p = 0.54) or U.S. Preventive Services Task Force (43.7% vs. 43.7%, p = 0.99) or higher rates of statin prescriptions (25.0% vs. 23.8%, p = 0.04). An additional 4.1% of primary prevention patients may be recommended for statin therapy if high CAD PRS were considered a guideline-based risk-enhancing factor.
CONCLUSIONS: Current paradigms for primary cardiovascular prevention incompletely capture a polygenic susceptibility to CAD. An opportunity may exist to improve CAD prevention efforts by integrating both genetic and clinical risk.
Copyright © 2020 American College of Cardiology Foundation. All rights reserved.

Entities:  

Keywords:  coronary artery disease; genetic risk; primary prevention; statin

Mesh:

Year:  2020        PMID: 32498804      PMCID: PMC7346975          DOI: 10.1016/j.jacc.2020.04.027

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  32 in total

Review 1.  AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee.

Authors:  Thomas A Pearson; Steven N Blair; Stephen R Daniels; Robert H Eckel; Joan M Fair; Stephen P Fortmann; Barry A Franklin; Larry B Goldstein; Philip Greenland; Scott M Grundy; Yuling Hong; Nancy Houston Miller; Ronald M Lauer; Ira S Ockene; Ralph L Sacco; James F Sallis; Sidney C Smith; Neil J Stone; Kathryn A Taubert
Journal:  Circulation       Date:  2002-07-16       Impact factor: 29.690

2.  Associations of Combined Genetic and Lifestyle Risks With Incident Cardiovascular Disease and Diabetes in the UK Biobank Study.

Authors:  M Abdullah Said; Niek Verweij; Pim van der Harst
Journal:  JAMA Cardiol       Date:  2018-08-01       Impact factor: 14.676

3.  A new initiative on precision medicine.

Authors:  Francis S Collins; Harold Varmus
Journal:  N Engl J Med       Date:  2015-01-30       Impact factor: 91.245

4.  Genetic identification of familial hypercholesterolemia within a single U.S. health care system.

Authors:  Noura S Abul-Husn; Kandamurugu Manickam; Laney K Jones; Eric A Wright; Dustin N Hartzel; Claudia Gonzaga-Jauregui; Colm O'Dushlaine; Joseph B Leader; H Lester Kirchner; D'Andra M Lindbuchler; Marci L Barr; Monica A Giovanni; Marylyn D Ritchie; John D Overton; Jeffrey G Reid; Raghu P R Metpally; Amr H Wardeh; Ingrid B Borecki; George D Yancopoulos; Aris Baras; Alan R Shuldiner; Omri Gottesman; David H Ledbetter; David J Carey; Frederick E Dewey; Michael F Murray
Journal:  Science       Date:  2016-12-23       Impact factor: 47.728

5.  Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement.

Authors:  Kirsten Bibbins-Domingo; David C Grossman; Susan J Curry; Karina W Davidson; John W Epling; Francisco A R García; Matthew W Gillman; Alex R Kemper; Alex H Krist; Ann E Kurth; C Seth Landefeld; Michael L LeFevre; Carol M Mangione; William R Phillips; Douglas K Owens; Maureen G Phipps; Michael P Pignone
Journal:  JAMA       Date:  2016-11-15       Impact factor: 56.272

Review 6.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.

Authors:  Sebhat Erqou; Stephen Kaptoge; Philip L Perry; Emanuele Di Angelantonio; Alexander Thompson; Ian R White; Santica M Marcovina; Rory Collins; Simon G Thompson; John Danesh
Journal:  JAMA       Date:  2009-07-22       Impact factor: 56.272

7.  Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease.

Authors:  Amit V Khera; Connor A Emdin; Isabel Drake; Pradeep Natarajan; Alexander G Bick; Nancy R Cook; Daniel I Chasman; Usman Baber; Roxana Mehran; Daniel J Rader; Valentin Fuster; Eric Boerwinkle; Olle Melander; Marju Orho-Melander; Paul M Ridker; Sekar Kathiresan
Journal:  N Engl J Med       Date:  2016-11-13       Impact factor: 91.245

8.  A Survey of U.S Adults' Opinions about Conduct of a Nationwide Precision Medicine Initiative® Cohort Study of Genes and Environment.

Authors:  David J Kaufman; Rebecca Baker; Lauren C Milner; Stephanie Devaney; Kathy L Hudson
Journal:  PLoS One       Date:  2016-08-17       Impact factor: 3.240

9.  A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease.

Authors:  Majid Nikpay; Anuj Goel; Hong-Hee Won; Leanne M Hall; Christina Willenborg; Stavroula Kanoni; Danish Saleheen; Theodosios Kyriakou; Christopher P Nelson; Jemma C Hopewell; Thomas R Webb; Lingyao Zeng; Abbas Dehghan; Maris Alver; Sebastian M Armasu; Kirsi Auro; Andrew Bjonnes; Daniel I Chasman; Shufeng Chen; Ian Ford; Nora Franceschini; Christian Gieger; Christopher Grace; Stefan Gustafsson; Jie Huang; Shih-Jen Hwang; Yun Kyoung Kim; Marcus E Kleber; King Wai Lau; Xiangfeng Lu; Yingchang Lu; Leo-Pekka Lyytikäinen; Evelin Mihailov; Alanna C Morrison; Natalia Pervjakova; Liming Qu; Lynda M Rose; Elias Salfati; Richa Saxena; Markus Scholz; Albert V Smith; Emmi Tikkanen; Andre Uitterlinden; Xueli Yang; Weihua Zhang; Wei Zhao; Mariza de Andrade; Paul S de Vries; Natalie R van Zuydam; Sonia S Anand; Lars Bertram; Frank Beutner; George Dedoussis; Philippe Frossard; Dominique Gauguier; Alison H Goodall; Omri Gottesman; Marc Haber; Bok-Ghee Han; Jianfeng Huang; Shapour Jalilzadeh; Thorsten Kessler; Inke R König; Lars Lannfelt; Wolfgang Lieb; Lars Lind; Cecilia M Lindgren; Marja-Liisa Lokki; Patrik K Magnusson; Nadeem H Mallick; Narinder Mehra; Thomas Meitinger; Fazal-Ur-Rehman Memon; Andrew P Morris; Markku S Nieminen; Nancy L Pedersen; Annette Peters; Loukianos S Rallidis; Asif Rasheed; Maria Samuel; Svati H Shah; Juha Sinisalo; Kathleen E Stirrups; Stella Trompet; Laiyuan Wang; Khan S Zaman; Diego Ardissino; Eric Boerwinkle; Ingrid B Borecki; Erwin P Bottinger; Julie E Buring; John C Chambers; Rory Collins; L Adrienne Cupples; John Danesh; Ilja Demuth; Roberto Elosua; Stephen E Epstein; Tõnu Esko; Mary F Feitosa; Oscar H Franco; Maria Grazia Franzosi; Christopher B Granger; Dongfeng Gu; Vilmundur Gudnason; Alistair S Hall; Anders Hamsten; Tamara B Harris; Stanley L Hazen; Christian Hengstenberg; Albert Hofman; Erik Ingelsson; Carlos Iribarren; J Wouter Jukema; Pekka J Karhunen; Bong-Jo Kim; Jaspal S Kooner; Iftikhar J Kullo; Terho Lehtimäki; Ruth J F Loos; Olle Melander; Andres Metspalu; Winfried März; Colin N Palmer; Markus Perola; Thomas Quertermous; Daniel J Rader; Paul M Ridker; Samuli Ripatti; Robert Roberts; Veikko Salomaa; Dharambir K Sanghera; Stephen M Schwartz; Udo Seedorf; Alexandre F Stewart; David J Stott; Joachim Thiery; Pierre A Zalloua; Christopher J O'Donnell; Muredach P Reilly; Themistocles L Assimes; John R Thompson; Jeanette Erdmann; Robert Clarke; Hugh Watkins; Sekar Kathiresan; Ruth McPherson; Panos Deloukas; Heribert Schunkert; Nilesh J Samani; Martin Farrall
Journal:  Nat Genet       Date:  2015-09-07       Impact factor: 38.330

10.  Comparing distributions of polygenic risk scores of type 2 diabetes and coronary heart disease within different populations.

Authors:  Sulev Reisberg; Tatjana Iljasenko; Kristi Läll; Krista Fischer; Jaak Vilo
Journal:  PLoS One       Date:  2017-07-05       Impact factor: 3.240

View more
  28 in total

Review 1.  Polygenic Risk Scores to Identify CVD Risk and Tailor Therapy: Hope or Hype?

Authors:  Charles A German; Michael D Shapiro
Journal:  Curr Atheroscler Rep       Date:  2021-06-28       Impact factor: 5.113

2.  Stratification of risk of progression to colectomy in ulcerative colitis via measured and predicted gene expression.

Authors:  Angela Mo; Sini Nagpal; Kyle Gettler; Talin Haritunians; Mamta Giri; Yael Haberman; Rebekah Karns; Jarod Prince; Dalia Arafat; Nai-Yun Hsu; Ling-Shiang Chuang; Carmen Argmann; Andrew Kasarskis; Mayte Suarez-Farinas; Nathan Gotman; Emebet Mengesha; Suresh Venkateswaran; Paul A Rufo; Susan S Baker; Cary G Sauer; James Markowitz; Marian D Pfefferkorn; Joel R Rosh; Brendan M Boyle; David R Mack; Robert N Baldassano; Sapana Shah; Neal S LeLeiko; Melvin B Heyman; Anne M Griffiths; Ashish S Patel; Joshua D Noe; Sonia Davis Thomas; Bruce J Aronow; Thomas D Walters; Dermot P B McGovern; Jeffrey S Hyams; Subra Kugathasan; Judy H Cho; Lee A Denson; Greg Gibson
Journal:  Am J Hum Genet       Date:  2021-08-26       Impact factor: 11.025

Review 3.  Use of Polygenic Risk Scores for Coronary Heart Disease in Ancestrally Diverse Populations.

Authors:  Ozan Dikilitas; Daniel J Schaid; Catherine Tcheandjieu; Shoa L Clarke; Themistocles L Assimes; Iftikhar J Kullo
Journal:  Curr Cardiol Rep       Date:  2022-07-07       Impact factor: 3.955

4.  Predictive Utility of a Validated Polygenic Risk Score for Long-Term Risk of Coronary Heart Disease in Young and Middle-Aged Adults.

Authors:  Sadiya S Khan; Courtney Page; Daniel M Wojdyla; Yosef Y Schwartz; Philip Greenland; Michael J Pencina
Journal:  Circulation       Date:  2022-07-26       Impact factor: 39.918

5.  Polygenic Risk Score to Identify Subclinical Coronary Heart Disease Risk in Young Adults.

Authors:  Quinn S Wells; Minoo Bagheri; Aaron W Aday; Deepak K Gupta; Christian M Shaffer; Wei-Qi Wei; Nataraja Sarna Vaitinadin; Sadiya S Khan; Philip Greenland; Thomas J Wang; C Michael Stein; Dan M Roden; Jonathan D Mosley
Journal:  Circ Genom Precis Med       Date:  2021-08-31

Review 6.  A Less than Provocative Approach for the Primary Prevention of CAD.

Authors:  Robert Roberts; Jacques Fair
Journal:  J Cardiovasc Transl Res       Date:  2021-06-14       Impact factor: 4.132

7.  Transethnic Transferability of a Genome-Wide Polygenic Score for Coronary Artery Disease.

Authors:  Sekar Kathiresan; Amit V Khera; Akl C Fahed; Krishna G Aragam; George Hindy; Yii-Der Ida Chen; Kumardeep Chaudhary; Amanda Dobbyn; Harlan M Krumholz; Wayne H H Sheu; Stephen S Rich; Jerome I Rotter; Rajiv Chowdhury; Judy Cho; Ron Do; Patrick T Ellinor
Journal:  Circ Genom Precis Med       Date:  2020-12-07

8.  Integrated Polygenic Tool Substantially Enhances Coronary Artery Disease Prediction.

Authors:  Vincent Plagnol; Peter Donnelly; Fernando Riveros-Mckay; Michael E Weale; Rachel Moore; Saskia Selzam; Eva Krapohl; R Michael Sivley; William A Tarran; Peter Sørensen; Alexander S Lachapelle; Jonathan A Griffiths; Ayden Saffari; John Deanfield; Chris C A Spencer; Julia Hippisley-Cox; David J Hunter; Jack W O'Sullivan; Euan A Ashley
Journal:  Circ Genom Precis Med       Date:  2021-03-02

9.  Prognostic Value of a Polygenic Risk Score for Coronary Heart Disease in Individuals Aged 70 Years and Older.

Authors:  Johannes T Neumann; Moeen Riaz; Andrew Bakshi; Galina Polekhina; Le T P Thao; Mark R Nelson; Robyn L Woods; Gad Abraham; Michael Inouye; Christopher M Reid; Andrew M Tonkin; John McNeil; Paul Lacaze
Journal:  Circ Genom Precis Med       Date:  2021-12-24

Review 10.  How Do We Incorporate Polygenic Risk Scores in Cardiovascular Disease Risk Assessment and Management?

Authors:  Trevor D Hadley; Ali M Agha; Christie M Ballantyne
Journal:  Curr Atheroscler Rep       Date:  2021-04-01       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.